Introduction
The c-myc proto-oncogene encodes a nuclear phosphoprotein that is inextricably linked to cell cycle regulation (Amati et al., 1998; Obaya et al., 1999) . Despite being induced by a wide range of mitogenic signals myc expression is usually tightly regulated in vivo; in part due to the short half-life of both the mRNA and the protein product (Dani et al., 1984; Hann and Eisenman, 1984) . However, its pivotal role in cell cycle progression makes it an important target for oncogenic deregulation and explains its widespread involvement in human neoplastic disease (Nesbit et al., 1999) . Forced expression of c-myc can drive quiescent cells into cycle, inhibit dierentiation and when coexpressed with an oncogenic partner such as ras, induce transformation in vitro (Land et al., 1983; Lachman and Skoultchi, 1984; Eilers et al., 1989) . Paradoxically over expression of myc can also result in apoptosis in growth restricting conditions. Prototype experiments revealed that the presence of Myc in serum deprived ®broblasts prevented quiescence and induced apoptosis. This and similar in vitro systems have been instrumental in identifying speci®c factors capable of blocking myc-induced cell death (Askew et al., 1991; Evan et al., 1992; Shi et al., 1992; Harrington et al., 1994; Polunovsky et al., 1996) . Myc can also sensitize cells to a variety of pro-apoptotic signals including those induced by hypoxia, p53, Fas, tumour necrosis factor a (TNFa), and certain anticancer drugs such as etoposide (for review see Prendergast, 1999) . The recent ®nding that Myc acts to mediate the release of cytochrome C from mitochondria, thus sensitizing cells to apoptosis, may explain its involvement in so many widely divergent cell death pathways (Juin et al., 1999) .
Mutational analysis has not been successful in separating the proliferative and apoptotic properties of the c-myc gene. Why a single gene should induce two such apparently contradictory, albeit context dependent, outcomes is not known. However, it has been hypothesized that the capacity of Myc to promote apoptosis, a feature shared with a number of other growth regulatory genes, may be an evolutionary conserved mechanism that limits the neoplastic potential of this and other proto-oncogenes (Evan and Littlewood, 1993; Evan et al., 1994) . The corollary of this hypothesis is that resistance to Myc-induced apoptosis is a prerequisite for tumour development and/or progression.
Transgenic studies have revealed that Myc can participate in the transformation of a wide variety of dierent cell types (Morgenbesser and DePinho, 1994) . However, the clonal nature of the tumours and variable latency that typi®es these models indicates the requirement for collaborating events (Adams et al., 1985; Stewart et al., 1993) , some of which may act to antagonize Myc-induced apoptosis. Conceivably a number of mechanisms may be instrumental in countering the apoptotic function of Myc in neoplastic cells including: activation of an autocrine pathway for survival; induction of a dominant inhibitor of apoptosis and loss of the cell death eector machinery. These mechanisms may act to reduce rather than abolish the apoptotic eects of Myc and need not be mutually exclusive.
Despite a wealth of in vitro data it has proved dicult to assess the importance of Myc-induced apoptosis in tumorigenesis in vivo. CD2-myc mice develop thymic lymphoma with an incidence of around 30% depending on genetic background (Stewart et al., 1993) . A characteristic feature of these tumours is the high level of spontaneous apoptosis observed, a ®nding that has also been reported for other myc expressing transgenics (Jacobsen et al., 1994; Hundley et al., 1997; Trudel et al., 1997 ). However it is not possible to deduce whether the high level of cell death observed within these lymphomas directly results from myc over expression or the altered state of the transformed cell.
This study was undertaken to test whether Myc behaviour in vivo parallels that seen in cell culture models and to investigate if resistance to Myc-induced apoptosis is an obligatory step in tumorigenesis. Using transgenic mice that express a regulatable Myc transgene in T-cells, we have shown that induction of Myc activity in thymic tissue can result in both proliferation and apoptosis, and that abrogating Myc induced apoptosis is not an essential requirement of tumour formation.
Results

Activation of mycER in thymocytes in vivo results in proliferation and apoptosis
To investigate the apoptotic and transforming properties of the proto-oncogene c-myc in vivo we introduced the CD2-mycER TM transgene construct into the germline of mice. The c-mycER TM component encodes a hybrid protein with the human c-myc cDNA fused to a mutated oestrogen receptor and is directed to the T-cell compartment by the CD2 locus control region (Zhumabekov et al., 1995) . The c-mycER TM construct has been extensively tested in vitro: treatment of cells with the oestrogen agonist/antagonist 4-hydroxytamoxifen induces Myc activity but no response is seen with oestrogen itself (Littlewood et al., 1995) . Four transgenic lines were produced, two of which (CD2-mycER TM -2 and CD2-mycER TM -15) were shown to express the construct in thymic tissues and were selected for further study. Transgene expression appeared to be within the normal physiological range and was not signi®cantly overexpressed compared to endogenous c-myc.
CD2-mycER TM transgenic mice show a proliferative response following a single injection of 4-hydroxytamoxifen (4-OHT). A signi®cant increase (P50.01) in total thymocyte number was detected within 24 h of treatment and was still evident after 48 h (Figure 1a) . No increase in thymocyte number was seen in mock treated transgenics or 4-OHT treated littermate controls indicating that the increased cell count seen in 4-OHT treated CD2-mycER TM mice was the result of induced myc activity. The proliferative response to myc upregulation was con®rmed by cell cycle analysis carried out 24 ± 48 h after 4-OHT treatment. Control mice showed no response but transgenic animals showed a signi®cantly greater proportion of cells in the S, G2 and M phases of the cell cycle (P50.01) and correspondingly fewer in G1 ( Figure  1b) .
Flow cytometry analysis of thymocyte subpopulations revealed that the increase in cell number was largely restricted to the CD4/CD8 double positive (DP) population (Figure 2 ). The absolute numbers of CD4 and CD8 single positive (SP) cells were not signi®cantly dierent from 4-OHT treated controls or mock treated transgenics. Double negative (DN) cells were reduced in CD2-mycER TM mice treated with 4-OHT, the dierence being small but signi®cant (P50.05). These results suggest that in addition to increased proliferation the expansion in this compartment may be due in part to accelerated transition from the DN to the DP stage.
To investigate the apoptotic role of Myc in vivo we examined thymic tissue from CD2-mycER TM mice 48 h following a single injection of 4-OHT. CD2-mycER TM mice injected with 4-OHT showed a signi®cant increase (P50.01) in apoptotic cells when compared to mock treated transgenics and 4-OHT treated controls ( Figure  3 ). Therefore, in addition to proliferation, Myc upregulation in thymocytes had a profound eect on levels of apoptosis within the thymus.
A similar eect was also observed when thymocytes were explanted in vitro. Although normal thymocytes have a limited lifespan in culture, CD2-mycER TM thymocytes treated with 4-OHT showed a significantly increased rate of cell death when compared to treated controls (P50.01). This eect was also seen to a lesser CD2-mycER TM mice have a low incidence of spontaneous thymic lymphoma which can be increased by activation of the transgene following tamoxifen treatment Untreated CD2-mycER TM transgenic mice show a moderate incidence of thymic lymphoma development with 23% (20/88) of line 15 and 21% (14/66) of line 2 developing tumours by 300 days of age. No littermate controls developed tumours during this period. As tamoxifen had not been administered to CD2-mycER TM mice this tumour rate represents a background eect, presumably due to basal transgene activity. When tamoxifen was administered to mice in the drinking water from birth the tumour incidence was signi®cantly greater with 62% (16/26) developing thymic lymphoma by 300 days of age (P50.01, Figure  5 ). Mice placed on treatment from 3 weeks of age displayed an intermediate incidence of 38% (11/29) .
Flow cytometry analysis revealed that CD2-mycER TM tumours displayed a remarkably consistent cellular phenotype with the majority of cells being CD4/CD8 DP. All (34/34) tumours arising from CD2-mycER TM mice were of this phenotype raising the possibility that this stage of thymocyte development may be particularly sensitive to myc-induced transformation.
Transformed cells retain their sensitivity to myc induced apoptosis in vitro
To investigate if myc-induced apoptosis was abolished in tumours arising from CD2-mycER TM mice we examined the eects of 4-OHT treatment on cell lines established from spontaneous thymic lymphomas, i.e. from CD2-mycER TM mice which had not been treated with tamoxifen. Although upregulation of Myc activity in CD2-mycER TM tumour cell lines increased the proportion of cells in cycle (data not shown) the predominant eect was to reduce overall viability of these lines. In total 12 independently arising tumour cell lines were tested and all showed signi®cantly reduced cell survival following 4-OHT treatment, representative survival curves are shown in Figure  6a ,b. To con®rm that the observed reduction in viability was the result of apoptosis, cells were stained with Annexin following 4-OHT treatment and analysed by¯ow cytometry ( Figure 7 ). To exclude the possibility that 4-OHT was intrinsically toxic to lymphoma cells four cell lines from CD2-myc transgenic mice, which express similar levels of Myc but without the Figure 6c ). Similar results were also seen with thymic tumour cells derived from three p53 null mice. Therefore, although a number of tumours with lowlevel Myc activity could be established in vitro, upregulating Myc in these lines severely compromised viability. These data show that CD2-mycER TM tumours retain their sensitivity to myc induced apoptosis and that there is no obligatory requirement for this pathway to be abrogated during the lymphomagenic process.
In contrast to Rat1 ®broblasts (Evan et al., 1992; Harrington et al., 1994 ) serum withdrawal did not accentuate Myc-induced apoptosis relative to untreated CD2-mycER TM lymphoma cell lines (data not shown). These lines were also used to investigate the eect of various T-cell cytokines on Myc mediated cell death. Although speci®c cytokines have been implicated as Tcell survival factors (Boise et al., 1995; Renauld et al., 1995) , none of the cytokines tested, I1-2, I1-4, I1-7 or I1-9 rescued the cells from myc-induced apoptosis (data not shown).
Myc induced apoptosis in T-lymphoma cells can occur in the absence of p53 and can be inhibited by the ectopic expression of Bcl-2
We have previously demonstrated strong synergy between deregulated myc and loss of p53 in T-cell lymphomas arising in CD2-myc transgenic mice (Blyth et al., 1995) . To investigate the mechanism(s) underlying this synergy we used TUNEL to assay the levels of apoptosis in a series of CD2-myc tumours that were either null or wild type for p53. Within each cohort there was considerable variation between tumours in the levels of cell death. However, the absence of p53 did not produce a signi®cant decrease in apoptotic rates in CD2-myc/p53 null tumours (Figure 8 ). To explore this issue further we derived tumour cell lines from CD2-mycER TM mice crossed on to a p53 null background. Three independently arising tumours from CD2-mycER TM /p53 null mice (not treated with tamoxifen) were established in vitro and tested. 4-OHT treatment induced signi®cant levels of death in all three tumours indicating that myc-induced apoptosis in transformed thymocyte cell lines was independent of p53 (a representative curve is shown in Figure 9a ). In contrast cell lines derived from spontaneous tumours of non-treated double transgenic mice expressing both mycER TM and bcl-2 in the T-cell compartment were resistant to the apoptotic eects of increased myc activity (Figure 9b ). These results suggest that in Tlymphoma cells, myc-induced death can be mediated by p53 independent pathways and that mechanisms other than the suppression of apoptosis are likely to be responsible for the synergy observed between myc and p53 loss.
Tumours retain sensitivity to apoptosis on transplantation and re-establishment Two CD2-mycER TM tumour cell lines were selected for transplantation studies. Line ER-41 responded to 4-OHT treatment in vitro by undergoing proliferation and apoptosis. Line TWr-46 became insensitive to 4-OHT treatment following prolonged passaging and failed to mediate myc-associated apoptosis. To date it has not been possible to elucidate the basis of this acquired resistance to myc-mediated apoptosis, however there is no evidence of obvious transgene deletion or rearrangement and the transgene is still expressed (data not shown). Mice injected with ER-41 cells which were administered tamoxifen in the drinking water survived longer than mock treated controls ( Figure  10a ). The dierence between the two groups was small but signi®cant (P50.05). Tamoxifen treatment had no eect on mice receiving line TWr-46 suggesting that the increased survival time of the experimental group was due to myc upregulation rather than non-speci®c eects of tamoxifen. Subcutaneous tumours were examined by TUNEL to assess the level of apoptosis in the tamoxifen treated group. Tumour tissue from mice receiving tamoxifen showed a signi®cantly higher number of apoptotic cells (P=0.019; Figure 10b ) suggesting that the retarded growth of tumours in the treated group may have been due to increased levels of apoptosis. No increase in apoptotic cells was observed in tamoxifen treated mice transplanted with the 4-OHT insensitive line (TWr-46).
Tumour nodules were recovered from mice transplanted with the tamoxifen sensitive cell line ER-41 and the cells explanted into culture. Lines ER-41-T2 and ER-41-T3 were derived from transplanted mice that were treated with tamoxifen and lines ER-41-E1 and ER-41-E3 were from mock treated controls. All four lines remained sensitive to the apoptotic eects of 4-OHT following re-establishment in vitro (Figure 10c) . Therefore despite the increased death of cells in vivo, selection for subclones resistant to myc induced apoptosis does not appear to have occurred, at least in the tumours tested.
Discussion
To investigate the role of Myc-induced apoptosis in vivo we have developed an inducible model using a chimeric construct that fuses c-myc to a modi®ed oestrogen receptor domain. Although some background transgene activity was clearly evident from the emergence of spontaneous tumours, increased activity could be induced both in vivo and in vitro. The results presented here show that de novo expression of myc within a normal cellular environment results in both proliferation and apoptosis, unequivocally establishing the physiological relevance of myc-induced apoptosis. Further this model demonstrates that mycinduced tumours do not accumulate secondary events that abrogate the apoptotic function of myc, and that increasing the level of myc activity within transformed cells can compromise tumour growth.
A variety of in vitro systems have ®rmly established Myc as an eector of cell death in growth limiting conditions. The factors and conditions which in¯uence the fate of cells expressing deregulated myc are diverse and often context dependent (Janicke et al., 1994; Klefstrom et al., 1994; Graeber et al., 1996; Li et al., 1996; Polunovsky et al., 1996; Dong et al., 1997; Hueber et al., 1997; Koumenis and Giaccia, 1997; Rupnow et al., 1998; Shim et al., 1998) . Transgenic systems have also provided evidence for the apoptotic role of Myc in both transformed (Jacobsen et al., 1994; Hundley et al., 1997; Santoni-Rugiu et al., 1998) and untransformed tissues (Trudel et al., 1997) and studies on T-cell hybridomas (Shi et al., 1992; Wang et al., 1998; Genestier et al., 1999) have suggested a role for myc-induced apoptosis in T-cell homeostasis. Such studies are, however, limited by the altered state of the tissues under study and the tissue modelling eects of constitutive transgene expression. As a result the factors governing the fate of cells expressing deregulated myc in vivo remain unclear. Here we show that a single tamoxifen treatment was sucient to induce an increase in the proportion of thymocytes in S phase as well as an increased apoptotic rate. The raised total cell number was entirely due to an increase in the CD4/ CD8 DP population suggesting that this developmental stage is uniquely sensitive to the eects of Myc. The ®nding that both proliferation and apoptosis were concurrent events is reminiscent of the apparently stochastic pattern of cell death observed in tissue culture systems (Evan et al., 1992) .
An interesting feature of this model is that untreated CD2-mycER TM mice show a background rate of spontaneous tumour formation. It is possible that these tumours arise following rare mutational or posttranslational events that serve to uncouple myc from the inhibitory ER domain. However it would appear more likely that they develop as a result of basal transgene activity, as cell lines derived from these tumours can be modulated by 4-OHT treatment and untreated CD2-mycER TM thymocytes show a small but signi®cant increase in apoptotic rate in vitro compared to littermate controls. Further, tumour development was only observed in transgenic lines with high copy number suggesting that the transgene showed some background activity that was functionally relevant when transgene expression levels were high.
Although CD2-mycER TM mice develop spontaneous lymphomas, tumour incidence could be modulated by tamoxifen with mice treated from birth showing a signi®cantly increased tumour incidence. Mice treated from 3 weeks of age showed an intermediate incidence.
Interestingly delaying treatment by 3 weeks did not signi®cantly alter the latency of neoplastic disease in those animals succumbing to thymic lymphoma but did have a marked aect on the long term risk of tumour development (62% versus 38%). It is possible that the timing of myc deregulation can qualitatively aect outcome and that during the neonatal period thymocytes may be particularly sensitive to the tumour initiating eects of myc.
It has been hypothesized that the apoptotic role of myc may serve to counterbalance its oncogenic potential (Evan and Littlewood, 1993; Evan et al., 1994; Hueber and Evan, 1998) . Available evidence might suggest that tumour cells expressing deregulated myc would initially proliferate but continued expansion would disrupt the tissue architecture and ultimately result in the transformed cells outgrowing their local supply of nutrients and cytokines. The high levels of Myc present in these stressed cells would signi®cantly compromise their survival leading to the arrest of tumour growth. In such a situation there would be very strong selection for events that abrogate the apoptotic function of Myc, a suggestion that is underscored by the observed synergy between myc and bcl-2 in transgenic models (Strasser et al., 1990) . However, c-myc induced apoptosis in T-cell lymphomas K Blyth et al this study has shown that fully malignant tumours arising from CD2-mycER TM mice remain highly sensitive to myc-induced apoptosis following explantation in vitro indicating that the apoptotic machinery that links myc to cell death remains intact. These results show that a dominant block to myc-induced apoptosis is not a prerequisite for tumour progression and suggest that continued tumour growth is likely to be dependent on a dynamic balance between cell proliferation and cell death, presumably maintained by both extrinsic and intrinsic survival pathways. The extensive cell death observed in primary and established CD2-mycER TM cell lines together with the increased apoptosis in transplanted tumours suggests that this balance can be perturbed by alterations in the level of myc activity. These ®ndings are supported by the observations of Prasad et al. (1997) who noted that apoptotic microfoci were correlated with ampli®ed levels of myc expression in tumours arising from Emmyc transgenic mice.
The requirement for p53 in myc-mediated apoptosis is unclear and may be tissue speci®c with some cell types having an obligatory requirement for p53 (Hermeking and Eick, 1994; Wagner et al., 1994) but others capable of transducing myc's apoptotic signal in the absence of p53 (Selvakumaran et al., 1994; Hsu et al., 1995; Lotem and Sachs, 1995; Sakamuro et al., 1995) . Previously we reported that loss of p53 resulted in a dramatic acceleration of thymic lymphomas in CD2-myc transgenic mice (Blyth et al., 1995) . To investigate the nature of this synergy we examined the apoptotic rates of CD2-myc/p53 wild type and CD2-myc/p53 null tumours but could detect no signi®cant dierence between the two groups. Further, high levels of cell death can be induced in CD2-mycER TM tumour cell lines null for p53. These results suggest that p53 does not restrict the oncogenic potential of Myc by abrogating its apoptotic function. Our data is consistent with that of Hsu et al. (1995) who showed in Em-myc mice that loss of p53 aected proliferation but not apoptosis in transformed tissues. The results presented here do not rule out the possibility that p53 is an important mediator of myc-induced apoptosis but do show that alternative pathways are available and suggest that other aspects of the tumour suppressor function of p53 may be more important in restricting myc-induced lymphomagenesis.
This study suggests a model for lymphomagenesis induced by over-expressed Myc as a balanced process in which the relative levels of proliferation and cell death dictate whether a tumour will progress or regress. Moreover, although we have shown that sensitivity to Myc-induced apoptosis is not lost in lymphoma development, it is clear that tumour cells have acquired secondary changes which favour proliferation over cell death. We suggest that the target genes for these changes are likely to be involved in the early steps of the bifurcating pathways leading from Myc to its alternative functional consequences. From our current knowledge of Myc-collaborating genes the critical functions may be the removal of checkpoints to proliferation (Blyth et al., 1995; Hsu et al., 1995) or the enhancement of survival and growth in the presence of limiting exogenous growth factors (Grimes et al., 1996; Vaillant et al., 1999) . Eludication of the relevant target genes and their functional interaction with over-expressed Myc will be the major focus of our future eorts.
Materials and methods
Transgenic mice
To generate CD2-mycER TM transgenic mice a human c-myc cDNA was fused to a mutated murine oestrogen receptor (Littlewood et al., 1995) and cloned into the multiple cloning region of the CD2 minigene vector VA hCD2 (Zhumabekov et al., 1995) . The 14 kb CD2-mycER TM restriction fragment was microinjected into C57B1/66CBA/Ca F2 fertilized eggs according to standard protocols (Hogan et al., 1994) . Genotypes of mice were identi®ed by Southern blot hybridization analysis on DNA extracted after tail biopsy. The generation of CD2-myc/p53 null mice has been described previously (Blyth et al., 1995) . Animals showing signs of cachexia were sacri®ced and examined.
DNA hybridization analysis
High molecular weight DNA was extracted from mouse tails and digested with appropriate restriction enzymes. Fragments were separated on 0.8% agarose gels and transferred to Hybond N membrane (Amersham Pharmacia Biotech Ltd, UK) in 106SSC. Filters were hybridised in QuikHyb (Stratagene) at 658C for 3 h, washed at high stringency (2615 min, 26SSC, 0.1% SDS followed by 2615 min, 0.26SSC, 0.1% SDS at 658C) and exposed to X-ray ®lm. CD2-mycER TM transgene sequences were detected using a human c-myc exon 3 restriction fragment (Stewart et al., 1993) radiolabelled by random priming using a-32 P-dCTP (3000 Ci/mole, Amersham Pharmacia Biotech Ltd, UK) to speci®c activities 45610 8 c.p.m./mg.
Tamoxifen administration
Short term activation of the CD2-mycER TM transgene was by a single injection of 4-hydroxytamoxifen (4-OHT). 4-OHT (Sigma, UK) was dissolved in ethanol (100 mg/ml), mixed with autoclaved sun¯ower seed oil (Sigma, UK, 10 mg/ml) and sonicated for approximately 20 min. Mice at 3 ± 5 weeks of age were injected intraperitoneally with 2 mg of 4-OHT. Mock treated mice were injected with ethanol mixed in oil (1 : 1000). Animals were sacri®ced 1 ± 7 days post injection. Long term administration of tamoxifen was by continued oral dosing in drinking water. Tamoxifen citrate (Sigma, UK) was made up weekly to 100 mg/ml in 1% ethanol.
Thymocyte preparation and viability assays
Thymus/tumour tissue was disaggregated aseptically using scalpel blades in complete RPMI 1640 medium (Gibco BRL, supplemented with 10% FCS, 2 mM glutamine, penicillin/ streptomycin and 50 mM b-mercaptoethanol). Viable lymphocytes were isolated on a Ficoll-Paque (Amersham Pharmacia Biotech Ltd, UK) density gradient at 3000 r.p.m. for 10 min and the cells washed in complete RPMI medium. Total cell number was assessed by trypan blue exclusion using 0.4% Trypan blue solution (Sigma). Cell viability assays were carried out in 24 or 96 well plates in complete RPMI medium with 1 ± 2610 6 cells/ml. Viable cell numbers were determined at 24 h intervals by trypan blue exclusion. All cultures were performed in triplicate or quadruplicate and viability curves were based on the average number of live cells expressed as a percentage of the average total. 4-hydroxytamoxifen (Semat) resuspended in ethanol (0.1 mM) was added to cells at a ®nal concentration of 250 nM. Equivalent volumes of ethanol were added to control cultures. Statistical analysis was carried out using Students t-test.
Flow cytometry analysis
Single cell suspensions were prepared as described above and washed in cold phosphate buered saline (PBS) containing 0.1% BSA and 0.01% sodium azide. 1 ± 2.5610 6 cells were directly labelled for 30 min at 48C using a combination of rat monoclonal antibodies: Quantum red (QR) conjugated anti-CD3 (Sigma); PE conjugated anti-CD4 (Sigma) and FITC conjugated anti-CD8 (Sigma/Serotec, UK). Cells were washed four times in cold PBS/BSA/sodium azide, resuspended in 200 ± 400 ml PBS/BSA/sodium azide and analysed on a Coulter Epics Elite. For the detection of apoptosis bȳ ow cytometry, 1610 6 cells were washed in PBS and centrifuged. The pellet was resuspended in Annexin-V-FLUOS (Boehringer Mannheim, UK) prepared in incubation buer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 5 mM CaCl 2 ) for 15 min at 48C as per manufactors instructions. As a positive control, cells were treated with 10 mM dexamethasone (Sigma) for 24 h. Samples were analysed on a Coulter Epics Elite.
Cell cycle analysis
Cells to a concentration of 3 ± 5610 6 were harvested by centrifugation and washed three times in sample buer (1 mg/ml glucose in PBS). Cells were centrifuged and the pellet vigorously vortexed in remaining¯uid (*0.2 ml). Cells were ®xed for a minimum of 18 h at 48C in ice cold 70% ethanol added dropwise. Following ®xation, samples were vortexed and centrifuged at high speed for 5 min. Cells were resuspended in residual ethanol by gentle vortex. Propidium iodide staining solution (50 mg/ml propidium iodide (Sigma) and 100 U/ml RNase A (Sigma) in 10 ml sample buer) was added to each sample. Samples were incubated at room temperature on a rocking platform for at least 30 min and analysed by¯ow cytometry within 6 h.
In situ apoptosis detection (TUNEL)
TdT-mediated, dUTP nick end labelling (TUNEL) was carried out on 10% neutral buered formalin ®xed, paran embedded tissue sections and is based on the procedure described by Gavrieli et al. (1992) . All incubations were carried out using 50 ± 100 ml of solution in a humidi®ed chamber at room temperature except where stated. After deparanization and rehydration, sections were incubated with 20 mg/ml proteinase K (Sigma) for 20 min and washed four times in PBS. Endogenous peroxidases were blocked by rinsing sections in 3% hydrogen peroxidase (Sigma) in methanol for 5 min. Sections were washed four times in PBS, immersed in TDT buer (30 mM Trizma base pH 7.2, 140 mM sodium cacodylate, 1 mM cobalt chloride in ultra pure water) for 2 min and then incubated for 60 min at 378C in TdT (0.15 ± 0.25 U/ml) and biotin-16-dUTP (1 : 50 ± 1 : 100, Boehringer Mannheim) diluted in TDT buer. Following two 5 min washes in TB buer (300 mM sodium chloride and 30 mM sodium citrate in ultra pure water) and four PBS washes, sections were incubated for 60 min with peroxidase conjugated streptavidin (Dako, UK). After two washes with PBS, staining was visualized using the chromogen AEC (Vector Laboratories, UK) and counterstained with Mayers haematoxylin. At least ®ve dierent microscopic ®elds were examined for each tissue section.
Transplantation experiments
MF1 Nu/Nu female mice at 9 ± 12 weeks of age were injected subcutaneously with 1610 7 cells from CD2-mycER TM lymphoma cell lines (ER-41 and TWr-46). Animals were administered tamoxifen by oral dosing in sterile drinking water as described above. Mock treated animals were given 1% ethanol in sterile water. Animals were humanely sacri®ced when subcutaneous tumour nodules were 2 cm in diameter. Tumours were ®xed in 10% formalin for TUNEL analysis.
